Table 1.
Patient characteristics*
| Characteristics | No. | Value |
|---|---|---|
| Age, mean ± SD years | 157 | 14.4 ± 3.0 |
| Age at onset of JIA, mean ± SD years | 157 | 8.9 ± 4.5 |
| Sex, female | 111 | 70.7 |
| JIA subtype | ||
| Oligoarticular JIA, persistent | 26 | 16.6 |
| Oligoarticular JIA, extended | 16 | 10.2 |
| Polyarticular JIA, RF negative | 62 | 39.5 |
| Polyarticular JIA, RF positive | 7 | 4.5 |
| Enthesitis‐related arthritis | 21 | 13.4 |
| Psoriatic arthritis | 11 | 7.0 |
| Undifferentiated arthritis | 0 | 0 |
| Systemic JIA | 4 | 2.5 |
| Chronic arthritis with other autoimmune inflammatory disease | 8 | 5.1 |
| Disease specifications | ||
| Disease duration, median (range) | 157 | 4.9 (0.18–16.8) |
| Physician assessment of disease activity, VAS score (range 0–100) † | 140 | 0 (0–50) |
| Number of joints with arthritis ‡ | ||
| No arthritis | 119 | 75.8 |
| Monoarthritis (1 joint) | 14 | 8.9 |
| Oligoarthritis (2–4 joints) | 11 | 7.0 |
| Polyarthritis (>4 joints) | 5 | 3.2 |
| Presence of uveitis | 26 | 16.6 |
| Medication at time point of evaluation | ||
| No medication | 60 | 39.0 |
| NSAIDs | 20 | 12.7 |
| MTX | 69 | 43.9 |
| Other DMARDs | 4 | 2.5 |
| Anti‐TNF | 45 | 28.7 |
| Other biologics | 2 | 1.3 |
| Multiple medications | 38 | 24.2 |
*
Values are the percentage unless indicated otherwise. JIA = juvenile idiopathic arthritis; RF = rheumatoid factor; VAS = visual analog scale; NSAIDs = nonsteroidal antiinflammatory drugs; MTX = methotrexate; DMARDs = disease‐modifying antirheumatic drugs; anti‐TNF = anti–tumor necrosis factor.
†
Physician VAS outcomes were missing for 17 patients at the time of measurement.
‡
Information on the number of infected joints was missing for 8 patients at the time of measurement.